At the 2026 J.P. Morgan Healthcare Conference, RNA therapeutics re-emerged as a pivotal force in genetic medicine, evolving from mere gene silencers to versatile tools for editing, repairing, and boosting gene function. This shift, highlighted in discussions with CEOs from Korro Bio, Trace Neuroscience, and CAMP4 Therapeutics, positions RNA as a flexible "middle ground" between irreversible DNA changes and traditional small molecules—offering precision for chronic diseases with lower risks.
Korro Bio Pioneers Natural RNA Editing
Korro Bio's CEO Ram Aiyar emphasized harnessing the body's own ADAR enzymes, which naturally convert adenosine to inosine in RNA. Their antisense oligonucleotides guide these edits without touching DNA, providing reversibility ideal for late-onset conditions like urea cycle disorders.
- Lead candidate KRRO-121 targets hepatic encephalopathy, editing one amino acid to stabilize enzymes and reduce ammonia levels with biweekly dosing.
- Preclinical results show nearly 100% editing efficiency in animals, expanding editable transcriptome targets.
- After halting an earlier alpha-1 program that fell short clinically, Korro streamlined for 2026 trials.
This approach avoids DNA editing's permanence, suiting diseases where transient fixes suffice.
Trace Neuroscience Targets ALS Splicing Defects
Trace Neuroscience CEO Eric Green focused on RNA splicing rescue for ALS, where TDP-43 dysfunction causes nearly all patients to lose UNC13A protein critical for synapses. Their ASO restores proper splicing, mirroring Spinraza's success in spinal muscular atrophy.
- In preclinical models, it potently replenishes UNC13A, addressing pathology in 97% of ALS cases.
- Intrathecal delivery ensures CNS penetration, with durability potentially needing only a few doses yearly.
- Broader potential in TDP-43-linked frontotemporal dementia and Alzheimer's subsets.
Rooted in human genetics, this validates ASOs for neurodegeneration beyond rare diseases.
CAMP4 Boosts Healthy Gene Expression
CAMP4 Therapeutics, led by CEO Josh Mendel Brehm and CFO Kelly Gold, flips the script by upregulating genes via regulatory non-coding RNAs. Antisense tech doubles expression from healthy alleles, perfect for haploinsufficiency like SYNGAP1-related epilepsy.
- Intrathecal dosing leverages proven CNS paths; clinic entry planned this year.
- Positioned as a platform with non-CNS partnerships, emphasizing capital efficiency.
This counters RNA's silencing legacy, filling gaps in neurodevelopmental therapies.
RNA's Rising Role in Precision Medicine
These innovations signal RNA therapeutics' maturation: editing tunes proteins, splicing rescues function, amplification restores output—all without DNA risks, backed by de-risked delivery. As genetic diseases burden healthcare, RNA's patient-centric flexibility could accelerate approvals, cut lifelong dosing needs, and expand to common conditions like neurodegeneration. With JPM 2026 underscoring urgency, investors and regulators eye this middle ground transforming medicine from reactive to restorative.
